Celgene, a multinational biopharmaceutical company, is poised to appoint an agency to its six-figure UK and Ireland communications business.
The firm will disclose its first retained agency for a market access, corporate, and brand public affairs account in the coming weeks, following a competitive pitch process.
Nicola Redfern, director of market access for the UK and Ireland at Celgene, is handling the process. She was recruited last June from pharmaceutical giant Novartis, where she was director of communications and external affairs in the firm's oncology business unit.
Celgene confirmed the process and said it did not previously have a retained agency, though it has worked with a number of shops on a project basis mainly on public affairs briefs. These are believed to have included Helen Johnson Consulting, though PRWeek UK understands the relationship covered ad hoc work last year. The agency is not involved in the pitch.
Celgene focuses on the discovery and development of products for the treatment of cancer and other severe immune conditions. It said there are more than 200 ongoing clinical trials at major medical centers worldwide using its compounds.
These are known as investigative compounds, which are being actively studied in clinical trials for patients with incurable hematological and solid tumor cancers, including chronic lymphocytic leukemia and ovarian cancer.
This story originally appeared on the website of PRWeek UK, the sister publication of PRWeek at Haymarket Media.